Article Text

Download PDFPDF
Correspondence on ‘Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab’
  1. Francesco Messina,
  2. Francesca Pampaloni,
  3. Stefano Piaserico
  1. Dermatology Unit, Department of Medicine, University of Padova, Padova, Italy
  1. Correspondence to Dr Stefano Piaserico, Department of Dermatology, Università degli Studi di Padova, 35122 Padova, Italy; stefano.piaserico{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with great interest the case of a recovery from COVID-19 in a man with spondyloarthritis treated with etanercept and methotrexate, described by Duret et al.1

We describe the case of a 53-year-old man suffering from psoriatic arthritis and psoriasis since he was 22, with no other medical conditions. He was previously treated with phototherapy, cyclosporine, methotrexate, acitretin, efalizumab and etanercept.

Since 2010, he was treated with ustekinumab (90 mg) with complete remission of both psoriatic arthritis and psoriasis. On 10 February 2020, he administered an injection of 90 mg ustekinumab. On 28 February, the patient developed low-grade fever, cough and general malaise. On 2 March, he was tested positive for Severe Acute Respiratory Syndrome (SARS) - Coronavirus (CoV)-2, after his office manager was discovered to be affected by COVID-19.

On 5 March, the …

View Full Text


  • Contributors FM performed the researches, wrote the paper and contributed to its revision. FP performed the researches and wrote the paper. SP conceived, wrote the paper and performed the revision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles